Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Depreciation & Amortization (CF) (2019 - 2025)

Revolution Medicines has reported Depreciation & Amortization (CF) over the past 7 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $2.3 million for Q4 2025, up 30.66% from a year ago — trailing twelve months through Dec 2025 was $7.8 million (up 18.62% YoY), and the annual figure for FY2025 was $7.8 million, up 18.62%.
  • Depreciation & Amortization (CF) for Q4 2025 was $2.3 million at Revolution Medicines, up from $2.1 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for RVMD hit a ceiling of $2.3 million in Q4 2025 and a floor of $671000.0 in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $1.3 million (2023), compared with a mean of $1.3 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): increased 6.17% in 2021 and later surged 37.94% in 2022.
  • Revolution Medicines' Depreciation & Amortization (CF) stood at $833000.0 in 2021, then surged by 37.94% to $1.1 million in 2022, then increased by 13.14% to $1.3 million in 2023, then skyrocketed by 33.46% to $1.7 million in 2024, then skyrocketed by 30.66% to $2.3 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $2.3 million (Q4 2025), $2.1 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.